Results Healthcare and Harel Consulting sign Cooperation Agreement to Facilitate Licensing in Emerging Markets
Results Healthcare, a healthcare advisory specialist that is part of the Results International Group, and Harel Consulting, a US-based business development consultancy with proprietary ties to leading pharmaceutical companies across the emerging markets, have signed a Cooperation Agreement.
According to the terms of the agreement, Results Healthcare will leverage its knowledge and relationships in the pharmaceutical and medical device sectors, particularly in Europe, to assist in identifying innovative companies that may become licensors for Harel Consulting’s Emerging Markets clients. Once the licensors are identified, the two companies may also work together to consummate the licensing deals.
Harel Consulting is led by Jacob Harel, a seasoned pharmaceutical executive with over 25 years of experience in the industry. Prior to founding Harel Consulting, he most recently served as Head of Corporate Business Development at Merck & Co., during which time he structured and negotiated a variety of deals around the globe and especially in Emerging Markets.
Kevin Bottomley, Managing Director at Results Healthcare commented on the agreement: “We are very pleased to have this opportunity to work with Harel Consulting. Jacob’s background enables him to see Emerging Markets opportunities from a developed world perspective. We believe that together we are well positioned to find the right opportunities for our clients in these markets.”
Jacob Harel, founder of Harel Consulting added: “Results Healthcare has an outstanding reputation for its knowledge and expertise in the pharmaceutical and medical devices sectors. Results Healthcare is well-suited to help us find, facilitate and execute licensing deals for our clients in Latin America, Eastern Europe, Middle East, Asia Pacific and Africa. We look forward to a fruitful collaboration.”
These future licensing deals are expected to bring more therapeutic choices to millions of patients in the Emerging Markets. Results Healthcare and Harel Consulting indicated that they are proud to make a contribution to the improvement of patients' health in these markets.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.